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Background: Drug resistance poses a signiﬁcant challenge for the
successful application of highly active antiretroviral therapy (HAART)
globally. Furthermore, emergence of HIV-1 isolates that preferentially
use CXCR4 as a coreceptor for cell entry, either as a consequence of
natural viral evolution or HAARTuse, may compromise the efﬁcacy of
CCR5 antagonists as alternative antiviral therapy.
Methods: We sequenced the pol gene of viruses from 45 individuals
failing at least 6 months of HAART in Durban, South Africa, to
determine the prevalence and patterns of drug-resistance mutations.
Coreceptor use proﬁles of theseviruses and those from 45HAART-naive
individuals were analyzed using phenotypic and genotypic approaches.
Results: Ninety-ﬁve percent of HAART-failing patients had at least
onedrug-resistantmutation.Thymidineanalogmutations(TAMs)were
presentin55% of patientswith9% of individuals possessingmutations
indicative of the TAM1 pathway, 44% had TAM2, whereas 7% had
mutations common to both pathways. Sixty percent of HAART-failing
subjects had X4/dual//mixed-tropic viruses compared with 30% of
HAART-naı ¨ve subjects (P , 0.02). Genetic coreceptor use prediction
algorithms correlated with phenotypic results with 60% of samples
from HAART-failing subjects predicted to possess CXCR4-using
(X4/dual/mixed viruses) versus 15% of HAART-naı ¨ve patients.
Conclusions: The high proportion of TAMs and X4/dual/mixed
HIV-1 viruses among patients failing therapy highlight the need for
intensiﬁed monitoring of patients taking HAARTand the problem of
diminished drug options (including CCR5 antagonists) for patients
failing therapy in resource-poor settings.
Key Words: coreceptor use, viral tropism, antiretroviral drug
resistance, HAART-failing patients, HAART-naı ¨ve patients
(J Acquir Immune Deﬁc Syndr 2011;58:233–240)
INTRODUCTION
HIV/AIDS is the leading cause of death in sub-Saharan
Africa and South Africa has the highest number of HIV
infections worldwide.
1 HIV-1 subtype C (HIV-1C) is re-
sponsible for the majority of infected individuals in South
Africa and worldwide.
2 Access to highly active antiretroviral
therapy (HAART) in South Africa has increased dramatically
since the launch of the Operational Plan for Comprehensive
HIV and AIDS Care and Treatment in 2003.
3 However,
antiretroviral drug coverage in sub-Saharan Africa remains
low and it was estimated that in 2009, only 37% of patients
eligible for treatment according to the World Health
Organization guidelines were receiving it.
4
Despite the suppression of HIV-1 plasma viral load by
HAART to undetectable levels, viral transcription persists
5,6 and
this canlead to the emergenceand persistence of drug resistance,
which has signiﬁcant public health implications. Most de-
veloping countries rely on clinical or immunologic algorithms to
monitor the effectiveness of HAART,
7 which may result in
a delay in the switching of failing HAART regimens. The delay
in the switching of failing HAART regimens in the developing
world, where World Health Organization guidelines recommend
the use of two nucleoside reverse transcriptase inhibitors
(NRTIs) and one nonnucleoside reverse transcriptase inhibitor
(NNRTI) as ﬁrst-line therapy, may in turn result in the
accumulation of thymidine analog mutations (TAMs), which
are associated with broad cross-resistance and may therefore
limit the options available for alternative regimens. Recent
studies have highlighted this emerging problem.
8–11
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TAMs in resource-poor settings, there are suggestive data that
individuals failing HAART may have a higher proportion of
CXCR4-using viruses compared with antiretroviral-naı ¨ve
patients even after controlling for the level of immunodeﬁ-
ciency between the groups.
12,13 CXCR4 (X4) and dual-tropic
(R5X4/dual) viruses are associated with rapid disease
progression and emerge in the late chronic phase of disease
in a signiﬁcant proportion of patients.
14,15 However, the switch
to X4 viruses appears to be signiﬁcantly less common for HIV-
1C, even in late stages of disease.
16–20 The predominant use of
CCR5 by HIV-1C could be interpreted to suggest that CCR5
antagonists would be more efﬁcacious for this subtype.
Therefore, characterization of viral tropism in HIV-1C could
help inform whether CCR5 antagonists should be used as
salvage therapy in patients failing current widely used
regimens or as part of ﬁrst-line/early regimens for maximum
beneﬁt.
We investigated the drug resistance mutational pathways
and factors associated with failure of HAARTamong HIV-1C-
infected patients in a setting where monitoring relies mainlyon
clinical and immunologic algorithms. Furthermore, we de-
termined coreceptor use proﬁles of HIV-1C viruses from
individuals initiating or failing HAART to assess the
usefulness of CCR5 antagonists as ﬁrst-line or salvage
therapy. We also explored the accuracy of env sequence-based
genotypic predictive algorithms in assessing the prevalence of
R5 and CXCR4-using viruses in these patients.
MATERIALS AND METHODS
Study Participants
Study participants were recruited from the Sinikithemba
outpatient HIV/AIDS clinic at McCord Hospital in Durban,
South Africa. Patients were included in the antiretroviral
therapy (ARV)-naı ¨ve cohort if they were at least 18 years of
age, had a known HIV infection, and had no history of
HAART (the use of single-dose nevirapine for the prevention
of mother-to-child HIV transmission was not an exclusion
criterion). Patients who met these criteria, had CD4+ T-cell
counts 200 cells/mm
3 or less, or displayed AIDS-deﬁning
clinical features according to World Health Organization
staging irrespective of CD4 counts or viral loads were
recruited into this study. Patients were included in the ARV-
failing arm if they were at least 18 years of age, had a known
HIVinfection, HIV-1 RNA load of 5,000 copies/mL orgreater,
and had at least 6 months of uninterrupted HAART. HAART-
failing patients were also recruited into the study if they were
clinically assessed to be failing therapy irrespective of viral
loads or CD4+ T-cell counts. All study participants gave
written informed consent and the study was approved by all
participating Institutional Review Boards.
Sample Collection, Viral Load, and
CD4 Measurement
CD4+ T-cell counts were determined from fresh blood from
all participants by standard ﬂow cytometry on a FACSCalibur
(Becton-Dickinson, Franklin Lakes, NJ) according to the
manufacturer’s instructions. Plasma viral loads were measured
using the COBAS AmpliPrep/COBAS Amplicor HIV-1 Monitor
Test, Version 1.5 (Roche Diagnostics, Rotkruez, Switzerland).
Genotypic Resistance Testing
Genotypic resistance testing was done from plasma
samples using the Viroseq HIV-1 Genotyping System (Celera
Diagnostics, Alameda, CA) as directed by the manufacturer.
Phenotypic Coreceptor Analysis
Coreceptor use of viruses from patient plasma samples
was determined using the enhanced sensitivity Troﬁle
coreceptor tropism assay (Monogram Biosciences Inc, South
San Francisco, CA).
21,22 The Troﬁle assay is a commercial,
standardized cell-based approach for determination of cor-
eceptor use by plasma-derived HIV-1 envelope proteins.
23,24
Envelope Sequence Analysis
cDNA synthesis, envelope ampliﬁcation, and cloning were
done as previously described.
25 Full-length env from 20 ARV-
failing patients and 20 ARV-naı ¨ve patients was cloned into the
pcDNA3.1D/V5-His-TOPO vector (Invitrogen, Carlsbad, CA).
Sequencing was done using the ABI PRISM Big Dye Terminator
Cycle Sequencing Ready Reaction kit Version 3.1 (Applied
Biosystems, CA). Sequences were assembled and edited using
Sequencher 4.8 (Ann Arbor, MI) and aligned with Mega 4.
26
Phylogenetic trees were constructed in Paup 4.0 (Sunderland,
MA) and visualized using Treeview 1.6.6 (Glasgow, Scotland).
Coreceptor use was predicted using various publicly available or
published sequence-based predictive algorithms.
27–30
Statistical Analysis
All statistical analysis was done using Graph Pad Prism
5. Factors associated with tropism were assessed using
unpaired t test, Fisher exact test, and logistic regression
analysis.
Nucleotide Sequence Accession Numbers
The sequence data obtained from this study have been
submitted to GenBank and are available under accession
numbers GU080160 to GU080199.
RESULTS
Demographic and Clinical Characteristics
Forty-ﬁve HAART-naı ¨ve and 45 HAART-failing patients
were recruited. Patient demographic and clinical data are
summarized in Table 1. At the time of analysis, HAART-naı ¨ve
patients had a lower median CD4+ T-cell count (123 cells/mm
3)
than HAART-failing (174 cells/mm
3)s u b j e c t s( P =0 . 0 3 6 ) .
However, the median CD4+ T-cell count of HAART-naı ¨ve
patients was higher than the nadir median CD4+ T-cell count
(57 cells/mm
3)( P = 0.0004) of HAART-failing patients.
HAART-naı ¨ve patients had a signiﬁcantly higher median
plasma viral load of 44,042 copies/mL compared with 6653
copies/mL for HAART-experienced participants (P =0 . 0 0 1 ) .
For patients failing treatment, the median duration on therapy
was 29 months.
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Drug resistance results were obtained for 43 of the
45 HAART-failing patients. Resistance testing was also
performed for 10 HAART-naı ¨ve patients. The only drug
resistance mutation observed in the HAART-naı ¨ve individuals
was in one patient with the NNRTI-associated E138A
mutation. Three HAART-naive patients had minor protease
inhibitor resistance mutations, one patient with mutations
L10V and T74S/T, another had mutation A71T, and the third
patient had the T74S/T mutation. Of the 45 HAART-failing
patients, 51.1% were on South African national treatment
guidelines Regimen 1A (Stavudine [d4T], Lamivudine [3TC],
and Efavirenz [EFV]); 4.4% were on Regimen 1B (d4T, 3TC,
and Nevirapine [NVP]); 29% were on Zidovudine (AZT), 3TC
and EFV; 8.9% were on AZT, 3TC, and NVP; 2.2% were on
AZT, d4T, Didanosine (ddI), and NVP; and 4.4% were on
AZT, d4T, 3TC, and EFV. Twenty-seven (60%) of the patients
were on previous ARV therapy as detailed in Table 1.
The speciﬁc drug resistance mutations detected in
HAART-failing patients and their frequencies are shown
in Figure 1. Mutations to all three major classes of drugs were
noted. Forty-one of the 43 (95%) ARV-failing patients pos-
sessed at least one drug resistance mutation. Ninety-one
percent of patients had at least one drug resistance mutation
against two classes of drugs (NRTI and NNRTI). Nineteen
percent had at least one resistance mutation against all three
classes of drugs (NRTI, NNRTI, and protease inhibitors). For
protease inhibitor, only one minor mutation (T74S) was
present in 9 (21%) of the HAART-failing patients (data
not shown).
M184V/I, present in 87% of HAART-failing patients,
was the most common NRTI mutation detected. TAMs were
detected in 55% of patients. The TAM1 pathway NRTI
mutations M41L and T215Y, associated with intermediate- to
high-level resistance to AZT and d4Tand low level resistance
to ddI,Abacavir, and TDF,
31 were present in approximately 9%
of patients. Neither an insertion at codon 69 nor the L210W
mutation, which is also indicative of the TAM1 pathway, was
noted. The TAM2 pathway mutations present were D67N,
K70R, T215F, and K219E/Q/R. Forty-four percent of patients
had TAM2 pathway mutations. Seven percent of patients
possessed both TAM1 and TAM2 mutations and 16% had
three or more TAMs.
Approximately 91% of patients had resistance to 3TC
and Emtricitabine, and 19% had high- or intermediate-level
resistance to AZTas deﬁned by the Stanford database resistance
scores (http://hivdb.stanford.edu/) (see also Figure 1 legend).
Fourteen percent had high- or intermediate-level resistance to
d4T, whereas 9% had high- or intermediate-level resistance to
ddI. High- or intermediate-level resistance to Abacavir was
noted in 28% of patients, whereas only 7% displayed high- or
intermediate-level resistance to TDF (Fig. 1A).
NNRTI mutations noted are summarized in Figure 1B.
The most common NNRTI resistance mutation was V106M,
found in 49% of HAART-failing participants. The K103N
(40%) and G190A (27%) mutations were also relatively
common but no G190S mutations were present in any of the
patients. V106M and K103N both cause high-level resistance
to three of the four NNRTI: nevirapine, delavirdine, and EFV
but has no effect on etravirine (ETR). G190A causes high-
level resistance to nevirapine, intermediate resistance to EFV,
and low-level resistance to ETR. This mutation also increases
susceptibility to delavirdine.
32 Interestingly, the M230L
mutation, associated with high-level resistance to ETR and
uncommon (less than 5%) in both Subtype B and C NNRTI-
failing patients, occurred at an unusually high frequency of
13.3% in this cohort. Ninety-ﬁve percent of patients had
mutations associated with high-level resistance to nevirapine;
93% had high-/intermediate-level EFV resistance mutations.
Ninety-three percent displayed high- or intermediate-level
resistance to delavirdine with 49% displaying high-/interme-
diate-level resistance to ETR (Fig. 1B).
Recent studies in southern Africa have highlighted the
growing problem of TAMs in patients receiving the World
Health Organization or national antiretroviral programs
recommended ﬁrst-line therapy.
9,10,33 We hypothesized that
these mutations may be increasing as antiretroviral rollout
accelerates accompanied by mainly clinical and immunologic-
based monitoring of treatment. We therefore compared the
proportion and patterns of TAM mutations observed in our
study, in which patients had been treated for a median of
29 months, with data reported from an earlier study from the
same healthcare facility in patients (median treatment duration
of 11 months) also following the South African national
antiretroviral treatment and monitoring guidelines. We found
that 55% of individuals failing therapy had TAM mutations
comparedwith32% reportedinthe earlier study
10 andtherewas
a nonsigniﬁcant trend in the present study for association of
TAMs with duration of treatment (P = 0.08) (data not shown).
TABLE 1. Patient Information
Patient Characteristic
ARV-Experienced
Patients Failing
Treatment (n = 45)
ARV-Naı ¨ve
Patients
(n = 45) P
Age, median years (Q1–Q3) 36 (24–51) 36 (20–78) 0.65
Gender: Female 28 (65%) 27 (60%)
Black race 45 (100%) 45 (100%)
CD4 cell count, median
cells/mm
3 (Q1–Q3)
Current 174 (9–718) 123 (8–660) 0.036
Nadir 57 (3–197) 0.0004
Viral load, median
copies/mL
6, 653
(225–220,010)
44,042
(1,702–1,167,759)
0.0010
Current treatment
regimen:
Regimen 1A
(d4T, 3TC, EFV) 23 (51.1%)
Regimen 1B
(d4T, 3TC, NVP) 2 (4.4%)
ZDV, d4T, ddI, NVP 1 (2.2%)
ZDV, d4T, 3TC, EFV 2 (4.4%)
ZDV, 3TC, EFV 13 (29.0%)
ZDV, 3TC, NVP 4 (8.9%)
3TC, Lamivudine; ARV, antiretroviral therapy; AZT, Zidovudine; d4T, Stavudine;
ddI, Didanosine; EFV, Efavirenz; NVP, Nevirapine; Q, quartile.
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Phenotypic Coreceptor Analysis
Only 83 of 90 samples were available for phenotypic
coreceptor analysis of which 75 samples (32 from ARV-
experienced patients failing treatment and 43 from ARV-naive
patients) yielded reportable data from the Troﬁle coreceptor
tropism assay. Overall, 31 of 75 (41%) were dual/mixed
viruses, 43 of 75 (57%) were CCR5-using, and only one (1%)
was exclusively CXCR4-using. Of the 43 ARV-naive patients,
30 (70%) possessed R5 viruses compared with 13 (30%) with
dual/mixed viruses. No ARV-naive patients exhibited exclu-
sive X4 viruses. Among the 32 ARV-experienced patients
failing treatment, 13 (41%) possessed R5 viruses, 18 (56%)
had dual/mixed infections, whereas one patient (3%) had
X4-only viruses (Fig. 2A). Thus, patients failing treatment had
a higher percentage (59%) of X4/dual/mixed viruses
compared with ARV-naive patients with 30%; ARV-naive
patients had a higher proportion of R5 viruses (70%)
compared with patients failing therapy with 41% (P = 0.02).
We then sought to determine if there was a relationship
among CD4 counts, viral loads, and viral tropism. Patients with
X4/dual/mixed viruses had signiﬁcantly lower nadir CD4+ T-
cell counts compared with those with R5 viruses in both the
ART-naive and ART-failing groups with signiﬁcant P values of
0.014 and 0.002, respectively. In logistic regression analysis,
lower CD4 counts (P = 0.0004) but not age of the patient
(P = 0.29) or duration on HAART (P = 0.95) treatment was
a signiﬁcant predictor of X4/dual/mixed infections. We also
investigated whether patients with TAMs were more likely to
harbor dual/mixed/X4 viruses. Eleven of 16 (69%) HAART-
failing patients with TAMs had X4/dual/mixed viruses and ﬁve
(31%) had CCR5-using viruses compared with the respective
proportions of 50% dual/mixed/X4 versus 50% R5 among
patients without TAMs (P = 0.47) (Fig. 2C).
Genotypic Analysis of the env Gene
HIV-1 envelope sequence determines coreceptor
use.
29,34–37 We therefore next sought to assess the extent to
which viral tropism could be predicted by env sequence
characteristics. We randomly selected 20 virologically failing
and 20 ARV-naı ¨ve patients and analyzed full-length env
sequences for predictive coreceptor use proﬁles.
FIGURE 1. Frequency of drug re-
sistance mutations and thymidine
analog resistance mutations (TAMs).
(A) The frequency of NRTI resistance
mutations, thymidine analog muta-
tion frequencies, and number of
patients displaying high- and inter-
mediate-level resistance to speciﬁc
NRTIs and (B) the frequency of
NNRTI resistance mutations and
the number of patients showing
resistance to speciﬁc NNRTIs.
According to the Stanford drug
resistance database algorithms for
interpretation of resistance, high-
level resistance refers to a genotypic
pattern in which isolates have the
maximum level of in vitro drug
resistance and/or patients infected
with isolates having similar geno-
types display little or no virologic
response to treatment with the drug.
In low-level resistance, virus isolates
have partial in vitro drug suscepti-
bility and/or patients with viruses of
thisgenotypemayhaveasuboptimal
virologic response to treatment com-
pared with the treatment of a wild-
type virus. Intermediate resistance
suggests a degree of drug resistance
greater than low-level resistance but
lower than high-level resistance.
NRTI, nucleoside reverse transcrip-
tase inhibitor; NNRTI, nonnucleoside
reverse transcriptase inhibitor.
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clustered with HIV-1C references (Fig. 3A, left panel). Phylo-
genetic analysis of the pol region also showed that all the patients
clustered with HIV-1C with the exception of 704MC012F, which
is a recombinant of subtypes A and G; 704MC003F, which is
a recombinant of Subtypes A and C; and 704MC006F, which
is a recombinant of Subtypes C and J as conﬁrmed using
Simplot (Fig. 3A, right panel). The env V3 loop sequences
from HAART-naı ¨ve and failing participants are shown in
Figure 3B. The overall V3 consensus sequence generated for
ARV-naive patients (right panel) had two more amino acids
than the consensus sequence generated for ARV-failing
patients (left panel). Thirteen (65%) of failures and
17 (85%) of ARV-naive patients had a V3 region consisting
of 35 amino acids consistent with the consensus Subtype
C sequence. Thirty-one of 40 (78%) clones analyzed contained
the consensus subtype C GPGQ crown motif sequence.
We next investigated the reliability of V3 loop sequence-
based predictive algorithms against the phenotypic results
obtained using the Troﬁle assay. Coreceptor prediction genotypic
methods evaluated here included the 11/25 rule, the overall net
V3 charge, the Subtype C-speciﬁc position speciﬁc scoring matrix
(C-PSSM), a web-based coreceptor prediction tool (http://indra.
mullins.microbiol.washington.edu/pssm/), and another web-based
coreceptor prediction tool, Geno2Pheno (http://coreceptor.bioinf.
mpi-inf.mpg.de/).
27–30 We also investigated whether a combined
algorithm (combining three of these four methods) would provide
a better correlate of the phenotype data. Overall, the combined
algorithm correlated with the Troﬁle assay results in 87% of cases,
compared with 81% for C-PSSM, 78% for the 11/25 rule and
75% for the V3 net charge method and 84% for Geno2Pheno
(Table 2). The combined algorithm and the 11/25 rule correctly
identiﬁed 90% of R5 sequences, C-PSSM correctly predicted
85%, and the V3 net charge method predicted 71% of R5 viruses,
whereas Geno2Pheno was accurate for 86% of R5 cases.
In contrast, the Geno2Pheno method was the best in accurately
predicting X4/dual/mixed at 82%, V3 overall charge method
accurately predicted 81% X4/dual/mixed, the combined algorithm
was at 80%, C-PSSM 72%, and the 11/25 rule correctly predicted
only 55% of X4/dual/mixed viruses. Sensitivity of these methods
was also determined using the Troﬁle assay as the gold standard.
The Geno2Pheno and V3 charge prediction methods were 82%
sensitive in predicting X4/dual/mixed virus variants followed
by the combined algorithm (80%), C-PSSM (73%), and 11/25
rule (46%).
DISCUSSION
Monitoring the emergence and patterns of antiretroviral
drug resistance is crucial for the success and sustainability of
treatment programs. Moreover, as new drugs become avail-
able, there is a growing need to better characterizevirusesfrom
both drug-naı ¨ve and virologically failing patients to better
understand the suitability of these new drugs either as
additional components of the current regimens or as salvage
therapy. In this study, we investigated the prevalence and
pattern of drug resistance mutations in a cohort of HIV-
1C-infected individuals failing therapy. In addition, because it
has previously been suggested that suboptimal ARVor certain
classes of drugs may select for the more virulent X4 virus
variants,
13 we sought to identify correlates of viral tropism in
HAART-naı ¨ve and therapy-experienced virologically failing
patients.
FIGURE 2. Relationship of viral tropism of ARV-naive and ARV-
failing patients. (A) Frequency of X4/dual/mixed- and R5-using
viruses in patients failing treatment and treatment-naive
individuals. Bar graph indicating results from the Troﬁle assay
comparing the proportion of patients with R5 viruses with
those harboring X4/dual/mixed viruses in HAART-naive versus
HAART-failing patients (P = 0.02, Fisher exact test). (B) CD4
counts and coreceptor use in HAART-naive patients and
HAART-failing patients. Dot graph indicating results from
Troﬁle assay. ARV-naive patients with X4/D/M viruses had
a lower CD4 count than ARV-naive patients with R5 viruses
(P = 0.014, unpaired t test). ARV-failing patients with X4/D/M
viruses had a lower CD4 count than ARV-failing patients with
R5 viruses (P = 0.02, unpaired t test). For ARV-failing patients,
nadir CD4 counts are represented. (C) Association of TAMs in
X4/D/ M viruses. Bar graph indicates troﬁle assay results. D/M
indicates dual/mixed viruses. ART, antiretroviral therapy;
HAART, highly active antiretroviral therapy; TAMs, thymidine
analog mutations.
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patients are receiving antiretroviral therapy according to
national and World Health Organization guidelines, 95% of
patients failing therapy had at least one drug resistance
mutation. The most common NRTI mutation was M184V/I in
87% of patients, with V106M/A (51%) and K103N (40%) the
most common NNRTI resistance mutations. These patterns are
consistent with data from previous HIV-1C studies.
10,38–40
However, we also found a high prevalence (13.3%) of the ETR
resistance-associated M230L mutation, which occurs rela-
tively rarely in NNRTI-failing patients. This ﬁnding may
require follow-up studies. Data from this study also revealed
that 55% of patients failing therapy had TAMs compared with
32% of patients studied from the same city in 2005 to 2006.
10
Recent studies from Botswana, Malawi, and South Africa have
also reported similar high proportions of TAMs in persons
failing therapyunder publicsector antiretroviral programswith
an apparent bias toward the TAM2 pathway in these Subtype C
studies.
33,41,42 In contrast, a recent Subtype B study showed
that 65% of virologically failing subjects harbored TAM1
pathway mutations
8 suggesting that there may be subtype-
speciﬁc differences in TAM pathways. Other reasons for TAM
pathway mutation differences may include differences in anti-
retroviral regimens, nadir CD4+ T-cell count before HAART
FIGURE 3. Neighbor-joining phylo-
genetic trees. (A) Left panel: neigh-
bor-Joining phylogenetic tree
constructed from the env gene se-
quences. All clones highlighted in red
cluster closely with subtype C. Right
panel: neighbor-joining phylogenetic
tree constructed from the pol gene
sequences. All patient samples high-
lighted in the red cluster together
withtheSubtypeCreferencewiththe
exception of 704MC012F, which
clusters with Subtype G. Bootstrap
values more than 70% are shown. (B)
Alignment of V3 sequences of clones
of ARV-failing and ARV-naı ¨ve patients.
The panel on the left indicates V3
sequences in patients failing treat-
ment and the panel on the right
indicates V3 sequences in ARV-naive
patients. The crown motif for each
sequence is highlighted in red. All
sequences from viruses determined
to be X4/dual/mixed by the Troﬁle
assay are highlighted in gray and
samples with asterisks next to the
samplenumber were notavailable for
analysis in the Troﬁle assay or did not
yield reportable data. ARV, antiretro-
viral therapy.
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tion on a failing regimen. Overall, we found that more than
90% of patients failing therapy had at least one drug resistance
mutation and 55% of patients harbored TAMs. To minimize
the loss of future treatment options, improved adherence
support mechanisms and better monitoring algorithms for
patients on HAART in resource-poor settings will be required.
We also investigated here whether HAART-failing HIV-
1C-infected patients had a higher proportion of X4/dual/mixed
viruses compared with HAART-naı ¨ve patients. Although we
found this to be the case, the patients failing HAART had lower
median (nadir) CD4+ counts compared with HAART-naı ¨ve
patients, and individuals possessing X4/dual/mixed viruses had
signiﬁcantly lower CD4+ T cell counts compared with those with
R5-only viruses in both the HAART-naı ¨ve and HAART-failing
arms of this study. These data therefore suggest that low CD4+
T-cellcounts(and byextensionthelengthof infection)rather than
HAART is the possible main cause of X4/dual/mixed viruses,
consistent with data from HIV-1 Subtype B studies.
12,41 However,
only a longitudinal study can decisively determine whether there
is higher proportion of emergence of X4/dual/mixed viruses in
treated versus HAART-naı ¨ve patients with similar CD4+ T-cell
counts. Nevertheless, our study underlines the importance of
introducing CCR5 inhibitors relatively early in the course of
HIV-1C infection for possible maximum beneﬁt and to preserve
otherdrugs for salvageuse. Clinicaltrialsareneeded todetermine
the equivalence or superiority of CCR5 inhibitors as part of ﬁrst-
line or early regimens rather than as salvage therapy in HIV-1C
settings.
Finally, the availability of virus phenotype and genotype
data allowed us to assess the use of V3 loop sequenced-based
methods for predicting viral tropism. Envelope sequence-
based genotypic coreceptor prediction algorithms offer
a simpler and less expensive means of analyzing viral tropism
in patients and could facilitate easier and less expensive
determination of whether a patient can be treated with CCR5
antagonists. Our data show that although genotypic methods
are reliable for a majority of cases, they failed to correctly
predict CXCR4 tropism in a signiﬁcant minority of cases
consistent with previous studies.
43 Although the Geno2Pheno
and V3 charge methods achieved more than 80% sensitivity in
predicting CXCR4/dual tropism for this data set, there remains
an urgent need to further investigate and develop better
predictive algorithms, perhaps taking into account sequences
outside of the V3 and more detailed analysis of V3 loop
sequences using newer technologies able to better characterize
V3 loop quasispecies diversity.
In summary, our observations conﬁrm and extend the
body of knowledge in examining coreceptor tropism directly
in patients failing currently recommended regimens and
comparing this with ARV-naı ¨ve patients in a HIV-1C setting.
The presence of high proportions of patients with TAMs
suggests that these mutations may be accumulating over time
in this population as a result of inadequate viral suppression,
perhaps as a consequence of poor immunologic and/or
clinically driven monitoring in the absence of viral load
testing. These results may suggest that in situations in which
virologic monitoring is not possible, measures are needed to
improve adherence and to develop better monitoring tools.
Comparison of the prevalence of CXCR4-using viruses
between ARV-naive before initiating ARTwith the prevalence
among treated patients revealed that there was a high
prevalence of X4/dual/mixed viruses in patients failing
treatment, possibly as a result of lower nadir CD4 counts in
these patients, underlining the need to investigate the possible
earlier use of CCR5 inhibitors before the development of
X4/dual/mixed viruses. Our data also highlight the usefulness
and limitations of genotypic coreceptor prediction methods in
assessing whether HIV-1C-infected patients can be put on
regimens that include CCR5 inhibitors. Longitudinal studies
on viral coreceptor evolution in HIV-1C infections are
warranted.
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